Travere Therapeutics (TVTX) Gross Profit (2016 - 2025)
Historic Gross Profit for Travere Therapeutics (TVTX) over the last 12 years, with Q3 2025 value amounting to $163.3 million.
- Travere Therapeutics' Gross Profit rose 16647.41% to $163.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $425.5 million, marking a year-over-year increase of 11967.3%. This contributed to the annual value of $225.4 million for FY2024, which is 6849.87% up from last year.
- Per Travere Therapeutics' latest filing, its Gross Profit stood at $163.3 million for Q3 2025, which was up 16647.41% from $112.9 million recorded in Q2 2025.
- Over the past 5 years, Travere Therapeutics' Gross Profit peaked at $163.3 million during Q3 2025, and registered a low of -$157.2 million during Q4 2021.
- Moreover, its 5-year median value for Gross Profit was $40.5 million (2023), whereas its average is $42.7 million.
- Its Gross Profit has fluctuated over the past 5 years, first crashed by 42134.08% in 2021, then soared by 16647.41% in 2025.
- Over the past 5 years, Travere Therapeutics' Gross Profit (Quarter) stood at -$157.2 million in 2021, then skyrocketed by 118.11% to $28.5 million in 2022, then soared by 42.23% to $40.5 million in 2023, then surged by 78.38% to $72.2 million in 2024, then surged by 126.03% to $163.3 million in 2025.
- Its Gross Profit stands at $163.3 million for Q3 2025, versus $112.9 million for Q2 2025 and $77.1 million for Q1 2025.